Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Johnson & Johnson Strikes Deal with Trump for Drug Discounts and Tariff Relief

by Team Lumida
January 9, 2026
in Markets
Reading Time: 3 mins read
A A
0
Johnson & Johnson Strikes Deal with Trump for Drug Discounts and Tariff Relief
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • Johnson & Johnson (J&J) agrees to lower drug prices for Americans in exchange for tariff exemption.
  • The deal includes offering drugs at international price levels for Medicaid and participating in the TrumpRx program.
  • J&J will build two manufacturing sites in the U.S. as part of a $55 billion investment plan.
  • The company is one of the last to finalize the agreement, with two major pharmaceutical firms, AbbVie and Regeneron, still in talks.

What Happened?
Johnson & Johnson (J&J) reached a deal with the U.S. government to lower its drug prices for some American consumers in exchange for tariff relief. As part of the agreement, J&J will provide drugs to Medicaid at prices aligned with those in other developed nations. Additionally, the company will participate in TrumpRx, a new program allowing patients to purchase discounted medications. This agreement is part of a broader initiative where 17 major pharmaceutical companies, including Roche and Novartis, have made similar price concessions. J&J is also committing to invest $55 billion in the U.S. by 2029, including the construction of two new manufacturing facilities.

Why It Matters?
This deal highlights the ongoing pressure on pharmaceutical companies to lower drug prices amid broader healthcare reform efforts. J&J’s commitment to expanding U.S. manufacturing aligns with the government’s push to encourage domestic production. The move also underscores the increasing trend of pharmaceutical companies balancing price reductions with tariff relief and manufacturing investments to maintain profitability. The lack of clear details regarding the tariff reprieve term is notable, as it may indicate ongoing negotiations on the extent of future trade benefits.

What’s Next?
Investors should watch for further developments in the ongoing talks with AbbVie and Regeneron, which could lead to similar agreements. Additionally, J&J’s upcoming announcements regarding further investments in U.S. manufacturing will provide more clarity on the company’s long-term strategy in response to this deal. The impact of these price reductions on J&J’s revenue and overall market positioning will be crucial to monitor, especially as the TrumpRx program rolls out.

Source
Previous Post

Wearable Health Devices: Helpful or Harmful to Our Well-Being?

Next Post

America’s Job Market Is Stalled — Low Unemployment Masks a Growing Hiring Freeze

Recommended For You

Nvidia’s 2031 Bond Yield Rises to 5.717% After Huang’s Exit, With $36 Billion of Neocloud Backstops Now Under Scrutiny

by Team Lumida
2 days ago

Nvidia’s 4.5% bond due 2031 yielded 5.717% on Friday, and analysts are questioning the company’s role in backing AI infrastructure after Jensen Huang’s exit.

Read more

S&P 500 Falls 0.4% and Nasdaq 0.91% on Friday as Nvidia Slides, but the Major Averages Notch Their Best Week Since August

by Team Lumida
2 days ago

The S&P 500 fell 0.4% and the Nasdaq 0.91% on Friday as Nvidia slid, but the major averages still scored their best week since August.

Read more

AI Borrowers Now Account for Almost Half of Long-Dated US Investment-Grade Issuance, With Hyperscaler Bond Sales Seen Near $250 Billion

by Team Lumida
4 days ago

AI-related borrowers now account for almost half of long-dated US investment-grade issuance, PIMCO said, urging credit diversifiers.

Read more

Nasdaq-100 Futures Slide 0.9% as Nvidia Falls More Than 8% After Hours, Leaving the Stock Down About 30% From Its Oct. 6 High

by Team Lumida
4 days ago

Nasdaq-100 futures fell 0.9% after Nvidia dropped more than 8% after hours on reports its board is preparing to oust CEO Jensen Huang.

Read more

CoreWeave Earnings Revive AI Outlook—168% Revenue Growth, FY Guidance Raised to $13-13.3B; Anthropic IPO Valuation Rebounds to $1.5T+; Nasdaq 100 Futures +1.5%; Bitcoin Steady $74K

by Team Lumida
5 days ago

CoreWeave Q3 revenue +168% YoY, net loss widened to $709M ($1.27/share) on higher interest costs. Raised FY2026 revenue guidance $13-13.3B. CRWV +10% premarket; AI infrastructure rally: IREN +6%,...

Read more

Gold Claws Back Toward $4,060 After a 2.6% Drop on Hot US CPI, Holding $4,000 as Traders Fully Price a December Fed Hike

by Team Lumida
5 days ago

Gold rose about 0.7% to $4,061.67 an ounce after a 2.6% slide on hot US inflation, holding $4,000 as traders fully price a December Fed hike.

Read more

SEC Penalties Sink to $1.1 Billion, the Lowest Since the 2008 Crisis, on 348 Enforcement Actions as Warren Readies Scrutiny of the Atkins SEC

by Team Lumida
5 days ago

The SEC obtained $1.1 billion in penalties last fiscal year, its lowest since 2008, on 348 actions as Democrats prepare to scrutinize its record.

Read more

Nasdaq-100 Futures Jump 1.43% After Nvidia’s 5.5% Slide and a Hot CPI Knocked the S&P 500 Down 0.38%, With December Hike Odds Near 90%

by Team Lumida
5 days ago

Stock futures rebounded early Wednesday after Nvidia’s slide and a hot October CPI pulled the S&P 500 down 0.38%, with December hike odds near 90%.

Read more

Fox Kicks Off an About $8 Billion High-Grade Bond Sale in Up to Seven Tranches to Repay the $8.4 Billion Bridge Loan Behind Its Roku Deal

by Team Lumida
5 days ago

Fox is seeking about $8 billion in up to seven investment-grade tranches to repay an $8.4 billion bridge loan used for its $22 billion Roku purchase.

Read more

Brent Breaks Below $90 for the First Time Since August as Trump Says the Iran War Could End ‘Fairly Soon,’ Though FGE Sees No Deal

by Team Lumida
5 days ago
Diesel Export Ban Would Hit Brazil, Chile and the UK Hardest While Gulf Coast Geography Blocks Relief for US Coasts

Brent touched $89.03, its lowest since Aug. 31, as Trump said the Iran war could end ‘fairly soon,’ but analysts warned the peace gap remains wide.

Read more
Next Post
America’s Job Market Is Stalled — Low Unemployment Masks a Growing Hiring Freeze

America’s Job Market Is Stalled — Low Unemployment Masks a Growing Hiring Freeze

Trump Pushes for Greenland Acquisition, Exploring Business Deals and Military Presence

Trump Targets Wall Street Landlords, Rattling Housing Stocks and Investor Confidence

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

white and black concrete building

Nike CEO Tells Staff He’s Tired of ‘Fixing’ the Business as Turnaround Stalls

April 2, 2026
a tug boat pulling a large container ship

U.S. Allies Still Await Tariff Relief on Autos and Steel Amid Trade Deal Uncertainties

August 20, 2025
September Rate Cut Likely as Job Market Risks Increase, Says Fed

Fed Faces Its Closest Rate Call in Years as Oil Shock, AI Demand, and Tariffs Revive Inflation Fears Ahead of July 28-29 Meeting

July 27, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018